Matthew Angel
CEO and President · Tempest Therapeutics, Inc.
IndividualBuying only
- 2026
- Jun 23, 2026
- 3
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Matthew Angel's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- GTCR INVESTMENT XI LLC - $639.50M in SHC purchases and sales in the last 12 months
- Keith A. Meister - $591.13M in ILMN purchases and sales in the last 12 months
- Ronda E. Stryker - $580.89M in SYK purchases and sales in the last 12 months
- Mozart Aggregator II LP - $579.20M in MDLN purchases and sales in the last 12 months
- TC Group VII S1, L.L.C. - $554.95M in MDLN purchases and sales in the last 12 months
- BERKSHIRE HATHAWAY INC - $488.34M in DVA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew Angel?
Matthew Angel is a corporate insider, tracked as CEO and President of Tempest Therapeutics, Inc. (TPST). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Matthew Angel last file a Form 4?
The most recent primary Form 4 on record is dated 23 June 2026, one of 3 filings going back to 2026.
Has Matthew Angel been buying or selling stock?
Recorded transactions: 4 open-market purchases ($1.00M) and 0 open-market sales across all tracked filings.
